Tests a self-collected HPV swab for cervical cancer screening in women
Tests a self-collected swab for HPV, a cause of cervical cancer.
Plain-language title generated from the registry record
Registry title: The Women's Screening and Self-Testing Program (PROMETA) Study
Key facts
- Where
- Maputo, MozambiqueSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 49 years old?
Source: NCT06810739, who can take part
Where in Mozambique
- University Eduardo Mondlane (UEM)Maputo, MozambiqueTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tulane University
- Trial code
- NCT06810739
- Record updated
- 20 July 2026
- Original description
This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (HIV) care and treatment services. The primary outcome of interest is the number of women screened and the proportion of screen-positive women undergoing treatment. Secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across Mozambique.Read full original descriptionShow less
A Hybrid Type III Effectiveness - Implementation, Pragmatic Intervention Trial for Cervical Cancer Screen and Treat in Mozambique
This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (HIV) care and treatment services. The primary outcome of interest is the number of women screened and the proportion of screen-positive women undergoing treatment. Secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across Mozambique.
Inclusion: Women 25-49 years; Accessing HIV care and treatment services; Not being pregnant; Patients with a cervix.
Exclusion: Physical or mental impairment that inhibits participation in the study; Pregnant women or <6 weeks post-partum; Women who have undergone a total hysterectomy with removal of the cervix.